Down-regulation of oxidative phosphorylation in the liver by expression of the ATPase inhibitory factor 1 induces a tumorpromoter metabolic state

Oncotarget

Volumn 7, Issue 1, 2016, Pages 490-508

  Santacatterina, Fulvio ^a,b,c   Sánchez Cenizo, Laura ^a,b,c   Formentini, Laura ^a,b,c   Mobasher, Maysa A ^d,e   Casas, Estela ^a,b,c   Rueda, Carlos B ^a,b,f   Martínez Reyes, Inmaculada ^a,b,c   de Arenas, Cristina Núñez ^a,b   García Bermúdez, Javier ^a,b,c   Zapata, Juan M ^d   Sánchez Aragó, María ^a,b,c   Satrústegui, Jorgina ^a,b,f   Valverde, ángela M ^d,e   Cuezva, José M ^a,b,c  

^a CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f Instituto de Investigación Sanitaria Fundación Jiménez Díaz   (Spain)

Author keywords

ATPase inhibitory factor 1; Cancer; Energy metabolism; Mitochondria; Reactive oxygen species

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE INHIBITORY FACTOR 1; DIETHYLNITROSAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PARACETAMOL; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; ATPASE INHIBITORY PROTEIN; PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; LIVER CANCER; LIVER CANCER CELL LINE; LIVER CARCINOGENESIS; LIVER CELL; LIVER MITOCHONDRION; MALE; METABOLISM; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PROTEIN EXPRESSION; TRANSGENE; ANIMAL; DRUG EFFECTS; ELECTRON MICROSCOPY; FLUORESCENCE MICROSCOPY; GENETICS; HUMAN; LIVER; LIVER TUMOR; MITOCHONDRION; MUTATION; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; ULTRASTRUCTURE; WESTERN BLOTTING;

ACETAMINOPHEN; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL SURVIVAL; DOWN-REGULATION; GENE EXPRESSION; HUMANS; LIVER; LIVER NEOPLASMS; MICE, TRANSGENIC; MICROSCOPY, ELECTRON; MICROSCOPY, FLUORESCENCE; MITOCHONDRIA; MUTATION; OXIDATIVE PHOSPHORYLATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84979925809     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/ONCOTARGET.6357     Document Type: Article

References (59)

1. Sanchez-Arago M, Formentini L and Cuezva JM. Mitochondria-mediated energy adaption in cancer: the H(+)-ATP synthase-geared switch of metabolism in human tumors. Antioxid Redox Signal. 2013; 19:285-298
2. Walker JE. The ATP synthase: the understood, the uncertain and the unknown. Biochem Soc Trans. 2013; 41:1-16
3. Vander Heiden MG, Cantley LC and Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324:1029-1033
4. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, Harry G, Hashimoto K, Porter CJ, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007; 11:37-51
5. Garcia-Cao I, Song MS, Hobbs RM, Laurent G, Giorgi C, de Boer VC, Anastasiou D, Ito K, Sasaki AT, Rameh L, Carracedo A, Vander Heiden MG, Cantley LC, et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell. 2012; 149:49-62
6. D'Errico I, Salvatore L, Murzilli S, Lo Sasso G, Latorre D, Martelli N, Egorova AV, Polishuck R, Madeyski-Bengtson K, Lelliott C, Vidal-Puig AJ, Seibel P, Villani G, et al. Peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1alpha) is a metabolic regulator of intestinal epithelial cell fate. Proc Natl Acad Sci U S A. 2011; 108:6603-6608
7. Matsuyama S, Xu Q, Velours J and Reed JC. The Mitochondrial F0F1-ATPase proton pump is required for function of the proapoptotic protein Bax in yeast and mammalian cells. Mol Cell. 1998; 1:327-336
8. Formentini L, Pereira MP, Sanchez-Cenizo L, Santacatterina F, Lucas JJ, Navarro C, Martinez-Serrano A and Cuezva JM. In vivo inhibition of the mitochondrial H+-ATP synthase in neurons promotes metabolic preconditioning. EMBO J. 2014; 33:762-778
9. Bernardi P. The mitochondrial permeability transition pore: a mystery solved? Front Physiol. 2013; 4:95
10. Alavian KN, Beutner G, Lazrove E, Sacchetti S, Park HA, Licznerski P, Li H, Nabili P, Hockensmith K, Graham M, Porter GA, Jr. and Jonas EA. An uncoupling channel within the c-subunit ring of the F1FO ATP synthase is the mitochondrial permeability transition pore. Proc Natl Acad Sci U S A. 2014; 111:10580-10585
11. Giorgio V, von Stockum S, Antoniel M, Fabbro A, Fogolari F, Forte M, Glick GD, Petronilli V, Zoratti M, Szabo I, Lippe G and Bernardi P. Dimers of mitochondrial ATP synthase form the permeability transition pore. Proc Natl Acad Sci U S A. 2013; 110:5887-5892
12. Chin RM, Fu X, Pai MY, Vergnes L, Hwang H, Deng G, Diep S, Lomenick B, Meli VS, Monsalve GC, Hu E, Whelan SA, Wang JX, et al. The metabolite alphaketoglutarate extends lifespan by inhibiting ATP synthase and TOR. Nature. 2014; 510:397-401
13. Sun X, Wheeler CT, Yolitz J, Laslo M, Alberico T, Sun Y, Song Q and Zou S. A Mitochondrial ATP Synthase Subunit Interacts with TOR Signaling to Modulate Protein Homeostasis and Lifespan in Drosophila. Cell Rep. 2014; 8:1781-1792
14. Formentini L, Sánchez-Aragó M, Sánchez-Cenizo L and Cuezva JM. The mitochondrial ATPase Inhibitory Factor 1 (IF1) triggers a ROS-mediated retrograde pro-survival and proliferative response. Mol Cell. 2012; 45:731-742
15. Sanchez-Cenizo L, Formentini L, Aldea M, Ortega AD, Garcia-Huerta P, Sanchez-Arago M and Cuezva JM. Upregulation of the ATPase inhibitory factor 1 (IF1) of the mitochondrial H+-ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype. J Biol Chem. 2010; 285:25308-25313
16. Sanchez-Arago M, Garcia-Bermudez J, Martinez-Reyes I, Santacatterina F and Cuezva JM. Degradation of IF1 controls energy metabolism during osteogenic differentiation of stem cells. EMBO Rep. 2013; 14:638-644
17. Faccenda D, Tan CH, Seraphim A, Duchen MR and Campanella M. IF1 limits the apoptotic-signalling cascade by preventing mitochondrial remodelling. Cell Death Differ. 2013; 20:686-697
18. Sanchez-Arago M, Formentini L, Martinez-Reyes I, Garcia-Bermudez J, Santacatterina F, Sanchez-Cenizo L, Willers IM, Aldea M, Najera L, Juarranz A, Lopez EC, Clofent J, Navarro C, et al. Expression, regulation and clinical relevance of the ATPase inhibitory factor 1 in human cancers. Oncogenesis. 2013; 2:e46
19. Song R, Song H, Liang Y, Yin D, Zhang H, Zheng T, Wang J, Lu Z, Song X, Pei T, Qin Y, Li Y, Xie C, et al. Reciprocal activation between ATPase inhibitory factor 1 and NFkappaB drives hepatocellular carcinoma angiogenesis and metastasis. Hepatology. 2014; 60:1659-1673
20. Onoda T, Ono T, Dhar DK, Yamanoi A, Fujii T and Nagasue N. Doxycycline inhibits cell proliferation and invasive potential: combination therapy with cyclooxygenase-2 inhibitor in human colorectal cancer cells. J Lab Clin Med. 2004; 143:207-216
21. Son K, Fujioka S, Iida T, Furukawa K, Fujita T, Yamada H, Chiao PJ and Yanaga K. Doxycycline induces apoptosis in PANC-1 pancreatic cancer cells. Anticancer Res. 2009; 29:3995-4003
22. Jovaisaite V, Mouchiroud L and Auwerx J. The mitochondrial unfolded protein response, a conserved stress response pathway with implications in health and disease. J Exp Biol. 2014; 217:137-143
23. Chen B, Liu L, Castonguay A, Maronpot RR, Anderson MW and You M. Dose-dependent ras mutation spectra in N-nitrosodiethylamine induced mouse liver tumors and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced mouse lung tumors. Carcinogenesis. 1993; 14:1603-1608
24. Finnberg N, Stenius U and Hogberg J. Heterozygous p53-deficient (+/-) mice develop fewer p53-negative preneoplastic focal liver lesions in response to treatment with diethylnitrosamine than do wild-type (+/+) mice. Cancer Lett. 2004; 207:149-155
25. Heindryckx F, Colle I and Van Vlierberghe H. Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol. 2009; 90:367-386
26. Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaria G, Kim H, Zapata JM, Marusawa H, Chamorro M and Reed JC. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res. 2002; 62:6674-6681
27. Cuezva JM, Ortega AD, Willers I, Sanchez-Cenizo L, Aldea M and Sanchez-Arago M. The tumor suppressor function of mitochondria: translation into the clinics. Biochim Biophys Acta. 2009; 1792:1145-1158
28. Mobasher MA, Gonzalez-Rodriguez A, Santamaria B, Ramos S, Martin MA, Goya L, Rada P, Letzig L, James LP, Cuadrado A, Martin-Perez J, Simpson KJ, Muntane J, et al. Protein tyrosine phosphatase 1B modulates GSK3beta/Nrf2 and IGFIR signaling pathways in acetaminophen-induced hepatotoxicity. Cell Death Dis. 2013; 4:e626
29. Dey R and Moraes CT. Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-x(L) in osteosarcoma cells. J Biol Chem. 2000; 275:7087-7094
30. Harris MH, Vander Heiden MG, Kron SJ and Thompson CB. Role of oxidative phosphorylation in Bax toxicity. Mol Cell Biol. 2000; 20:3590-3596
31. Bonora M, Bononi A, De Marchi E, Giorgi C, Lebiedzinska M, Marchi S, Patergnani S, Rimessi A, Suski JM, Wojtala A, Wieckowski MR, Kroemer G, Galluzzi L, et al. Role of the c subunit of the FO ATP synthase in mitochondrial permeability transition. Cell Cycle. 2013; 12:674-683
32. Carraro M, Giorgio V, Sileikyte J, Sartori G, Forte M, Lippe G, Zoratti M, Szabo I and Bernardi P. Channel formation by yeast F-ATP synthase and the role of dimerization in the mitochondrial permeability transition. J Biol Chem. 2014; 289:15980-15985
33. Minauro-Sanmiguel F, Wilkens S and Garcia JJ. Structure of dimeric mitochondrial ATP synthase: novel F0 bridging features and the structural basis of mitochondrial cristae biogenesis. Proc Natl Acad Sci U S A. 2005; 102:12356-12358
34. Campanella M, Casswell E, Chong S, Farah Z, Wieckowski MR, Abramov AY, Tinker A and Duchen MR. Regulation of mitochondrial structure and function by the F1Fo-ATPase inhibitor protein, IF1. Cell Metab. 2008; 8:13-25
35. Rahman M, Nirala NK, Singh A, Zhu LJ, Taguchi K, Bamba T, Fukusaki E, Shaw LM, Lambright DG, Acharya JK and Acharya UR. Drosophila Sirt2/mammalian SIRT3 deacetylates ATP synthase beta and regulates complex V activity. J Cell Biol. 2014; 206:289-305
36. Vassilopoulos A, Pennington JD, Andresson T, Rees DM, Bosley AD, Fearnley IM, Ham A, Flynn CR, Hill S, Rose KL, Kim HS, Deng CX, Walker JE, et al. SIRT3 deacetylates ATP synthase F1 complex proteins in response to nutrient-and exercise-induced stress. Antioxid Redox Signal. 2014; 21:551-564
37. Brouard S, Otterbein LE, Anrather J, Tobiasch E, Bach FH, Choi AM and Soares MP. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med. 2000; 192:1015-1026
38. Karin M and Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005; 5:749-759
39. Lapuente-Brun E, Moreno-Loshuertos R, Acin-Perez R, Latorre-Pellicer A, Colas C, Balsa E, Perales-Clemente E, Quiros PM, Calvo E, Rodriguez-Hernandez MA, Navas P, Cruz R, Carracedo A, et al. Supercomplex assembly determines electron flux in the mitochondrial electron transport chain. Science. 2013; 340:1567-1570
40. Serrano M and Blasco MA. Cancer and ageing: convergent and divergent mechanisms. Nat Rev Mol Cell Biol. 2007; 8:715-722
41. Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G and Karin M. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogeninduced compensatory proliferation and liver tumorigenesis. Cancer Cell. 2008; 14:156-165
42. Yin T, Lu L, Xiong Z, Wei S and Cui D. ATPase inhibitory factor 1 is a prognostic marker and contributes to proliferation and invasion of human gastric cancer cells. Biomed Pharmacother. 2015; 70:90-96
43. Wei S, Fukuhara H, Kawada C, Kurabayashi A, Furihata M, Ogura S, Inoue K and Shuin T. Silencing of ATPase Inhibitory Factor 1 inhibits cell growth via cell cycle arrest in bladder cancer. Pathobiology. 2015; 82:224-232
44. Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z, Hurren R, Jitkova Y, Gronda M, Maclean N, Lai CK, Eberhard Y, Bartoszko J, et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2011; 20:674-688
45. Lamb R, Ozsvari B, Lisanti CL, Tanowitz HB, Howell A, Martinez-Outschoorn UE, Sotgia F and Lisanti MP. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. Oncotarget. 2015; 6:4569-4584 Doi: 10.18632/oncotarget.3174
46. Nishikawa T, Bellance N, Damm A, Bing H, Zhu Z, Handa K, Yovchev MI, Sehgal V, Moss TJ, Oertel M, Ram PT, Pipinos, II, Soto-Gutierrez A, et al. A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease. J Hepatol. 2014; 60:1203-1211
47. Black D, Bird MA, Samson CM, Lyman S, Lange PA, Schrum LW, Qian T, Lemasters JJ, Brenner DA, Rippe RA and Behrns KE. Primary cirrhotic hepatocytes resist TGFbeta-induced apoptosis through a ROS-dependent mechanism. J Hepatol. 2004; 40:942-951
48. Raval J, Lyman S, Nitta T, Mohuczy D, Lemasters JJ, Kim JS and Behrns KE. Basal reactive oxygen species determine the susceptibility to apoptosis in cirrhotic hepatocytes. Free Radic Biol Med. 2006; 41:1645-1654
49. Mihaylova MM and Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 2011; 13:1016-1023
50. Shao D, Oka S, Liu T, Zhai P, Ago T, Sciarretta S, Li H and Sadoshima J. A redox-dependent mechanism for regulation of AMPK activation by Thioredoxin1 during energy starvation. Cell Metab. 2014; 19:232-245
51. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A and Nebreda AR. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell. 2007; 11:191-205
52. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006; 441:431-436
53. Acebo P, Giner D, Calvo P, Blanco-Rivero A, Ortega AD, Fernandez PL, Roncador G, Fernandez-Malave E, Chamorro M and Cuezva JM. Cancer abolishes the tissue type-specific differences in the phenotype of energetic metabolism. Transl Oncol. 2009; 2:138-145
54. Santacatterina F, Chamorro M, Nuñez de Arenas C, Navarro C, Martin MA, Cuezva JM and Sánchez-Aragó M. Quantitative analysis of proteins of metabolism by reverse phase protein microarrays identifies potential biomarkers of rare neuromuscular diseases. J Trans Med. 2015; 13:65
55. Barrientos A, Fontanesi F and Diaz F. Evaluation of the mitochondrial respiratory chain and oxidative phosphorylation system using polarography and spectrophotometric enzyme assays. Curr Protoc Hum Genet. 2009; 19:13
56. Wittig I, Carrozzo R, Santorelli FM and Schagger H. Functional assays in high-resolution clear native gels to quantify mitochondrial complexes in human biopsies and cell lines. Electrophoresis. 2007; 28:3811-3820
57. Traba J, Del Arco A, Duchen MR, Szabadkai G and Satrustegui J. SCaMC-1 promotes cancer cell survival by desensitizing mitochondrial permeability transition via ATP/ADP-mediated matrix Ca(2+) buffering. Cell Death Differ. 2012; 19:650-660
58. Amigo I, Traba J, Gonzalez-Barroso MM, Rueda CB, Fernandez M, Rial E, Sanchez A, Satrustegui J and Del Arco A. Glucagon regulation of oxidative phosphorylation requires an increase in matrix adenine nucleotide content through Ca2+ activation of the mitochondrial ATP-Mg/Pi carrier SCaMC-3. J Biol Chem. 2013; 288:7791-7802
59. Yun J and Finkel T. Mitohormesis. Cell Metab. 2014; 19:757-766